3T Biosciences
3tbiosciences.com
Actively hiring
Drug Discovery
Oncology Therapeutics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
2
CRV, Westlake BioPartners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2017
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
CRV 
Westlake BioPartners Similar startupsby what they do, their industry and backers
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves…
Protai leverages proteomics and AI to accelerate drug discovery, enabling faster identification of novel therapeutic targets and biomarkers.
Learn how Dispatch Biotherapeutics is expanding the curative potential of immunotherapies by dispatching its Flare platform to overcome…
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
News
3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations
Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., - March 2, 2026 - 3T Biosciences, an immunoth
Read more
Report
3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors
Kharabi led development of CD19 CAR-T therapy TECARTUS; brings extensive cell and gene therapy expertise to guide 3T's bispecific T-cell engager programs into the clinic Knudsen oversees more than 100 immunotherapy studies at PICI; adds deep translational
Read more
Report
3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors
3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointmen...
Read more
Report
3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors
3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors
Read more
Report
Pro access
Upgrade to see all 17 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.